Publications by authors named "Craig Elkins"
Article Synopsis
- A clinical trial assessed the Cross-Seal vascular closure device's ability to effectively and safely achieve hemostasis in patients using large sheaths (8F-18F) for interventional procedures.
- Conducted on 147 participants, the trial showed a quick average time to hemostasis of just 0.4 minutes, with high technical success (92.3%) and a low rate of major complications (5.7%).
- Results indicate that the Cross-Seal device is a safe and effective option for patients undergoing percutaneous endovascular procedures with large-bore access.
Left ventricular assist devices (LVADs) are blood pumps that augment the function of the failing heart to improve perfusion, resulting in improved survival. For LVADs to effectively unload the left ventricle, the inflow cannula (IC) should be unobstructed and ideally aligned with the heart's mitral valve (MV). We examined IC orientation deviation from a hypothesized conventional angle (45° right-posterior) and the approximate angle for direct IC-MV alignment in many patients.
View Article and Find Full Text PDFThe HeartMate II left ventricular assist device (LVAD) is a small axial-flow next-generation pump. Acute stoppage of this device is a potentially lethal complication. As these devices proliferate, many patients will be in areas remote to their implant center.
View Article and Find Full Text PDFObjective: We performed a review of a consecutive series of 487 patients undergoing the Ross operation to identify surgical techniques and clinical parameters that affect outcome.
Methods: We performed a prospective review of consecutive patients from August 1986 through June 2002 and follow-up through August 2004. Patient age was 2 days to 62 years (median, 24 years), and 197 patients were less than 18 years of age.